Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Last trade$14.80
Day change-$0.005 (-0.03%)
Day range$14.13 – $15.58
Volume2,209,113
Market cap$1.60B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.6B
Price / earnings
—
Price / book
7.54×
Price / sales
19.86×
EV / sales
18.65×
EV / EBITDA
-12.89×
Profitability
Earnings per share
-$1.10
Return on assets
-40.92%
Return on equity
-56.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.53×
Quick ratio
4.38×
Cash ratio
1.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$107.69M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PSNL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$25.6M
$22.36M
$15.47M
$17.35M
$14.5M
$17.2M
$20.61M
$16.8M
Cost of revenue
$19.03M
$17.61M
$15.19M
$15.45M
$12.58M
$12.45M
$13.4M
$12.25M
Gross profit
$6.57M
$4.74M
$281K
$1.9M
$1.91M
$4.76M
$7.21M
$4.55M
Selling, general and administrative
$26.01M
$22M
$17.9M
$14.09M
$13.03M
$14.18M
$12.26M
$11.17M
Research and development
$16.07M
$16.34M
$14.54M
$13.07M
$12.17M
$12.38M
$12.64M
$11.49M
Total operating expenses
$42.09M
$38.33M
$32.44M
$27.17M
$25.21M
$26.56M
$24.9M
$22.66M
Operating income
-$35.52M
-$33.59M
-$32.16M
-$25.27M
-$23.29M
-$21.8M
-$17.7M
-$18.11M
Interest expense
-$36K
-$37K
-$47K
-$65K
-$64K
-$48K
-$28K
$1K
Income before taxes
-$33.8M
-$31.68M
-$30.02M
-$23.8M
-$21.65M
-$20.05M
-$15.74M
-$16.42M
Income taxes
$3K
$5K
$16K
$9K
$3K
$2K
$7K
$4K
Net income
-$33.8M
-$31.68M
-$30.03M
-$23.81M
-$21.65M
-$20.06M
-$15.75M
-$16.43M
Net income attributable to common shareholders
-$33.8M
-$31.68M
-$30.03M
-$23.81M
-$21.65M
-$20.06M
-$15.75M
-$16.43M
EBITDA
-$33.04M
-$31.18M
-$29.79M
-$22.8M
-$20.83M
-$19.27M
-$15.11M
-$15.57M
Basic earnings per share
-$0.32
-$0.30
-$0.29
-$0.26
-$0.24
-$0.23
-$0.18
-$0.23
Diluted earnings per share
-$0.32
-$0.30
-$0.29
-$0.26
-$0.24
-$0.23
-$0.18
-$0.23
Recent news
Company coverage with links to the original publishers.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).
Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.
Law firm Wohl & Fruchter is investigating whether the Personalis board acted in shareholders' best interests regarding the proposed $16.25 per share sale to Tempus AI. Since the announcement on July 20, 2026, Personalis shares have fallen approximately 14% due to the deal's partial stock consideration and Tempus share price decline. Shareholders have expressed disappointment with the transaction.
Law firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.